Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Company Performance - Worldwide net trade sales of DARZALEX® in Q3 2024 totaled USD 3,016 million, with USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world [1] - Genmab receives royalties on worldwide net sales of DARZALEX®, including both intravenous and subcutaneous products, under an exclusive license to Janssen Biotech, Inc [1] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives [2] - The company has a 25-year history of inventing next-generation antibody technology platforms, including bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators [2] - Genmab's vision is to transform the lives of people with cancer and serious diseases by 2030 through its KYSO® antibody medicines [2] Corporate Structure - Genmab was established in 1999 and is headquartered in Copenhagen, Denmark [3] - The company has an international presence across North America, Europe, and Asia Pacific [3]